Menu Menu

News

Featured
COVID-19 Research Pipeline

71,455

Registered/ Published

3,208

Registered

369

Published

4,701

Registered
As at 22 July 2021
FILTERED BY > Tocilizumab Clear filter

Guidelines update, v38.3

13 May, 2021
Updates to the Australian guidelines for the clinical care of people with COVID-19 this week include the following changes to the evidence summary sections for:   Convalescent plasma We have found one new study comparing convalescent plasma with standard care (Koerper et al. medRxiv doi: 10.1101/2021.05.10.21256192). Tocilizumab We have found two new studies comparing tocilizumab with standard care (Rutgers et al....
News

Communique # 42

22 April, 2021
Message from the Chair and Executive Director Dear Colleagues We’ve just passed 12-months since the first publication of the Australian clinical guidelines for the care of people with COVID-19....
Communique

Communique # 40

18 March, 2021
WEEK IN REVIEW UPDATES TO THE LIVING GUIDELINE New recommendation for tocilizumab in children or adolescents Further to the Taskforce's recent recommendation for the conditional use of tocilizumab for adults (25...
Communique

Guidelines update, v35.2

11 March, 2021
Updates to the Australian guidelines for the clinical care of people with COVID-19 this week include:   Tocilizumab - The reference for one included study (Wang et al.) was...
News

Guidelines update, v35.1

4 March, 2021
Updates to the Australian guidelines for the clinical care of people with COVID-19 this week include: Tocilizumab - The references for REMAP-CAP and COVACTA (Rosas et al.) trials have...
News

Communique # 39

25 February, 2021
WEEK IN REVIEW UPDATES TO THE LIVING GUIDELINE Tocilizumab upgraded to conditional recommendation The Taskforce Disease Modifying Treatment and Chemoprophylaxis Panel and the Guidelines Leadership Group have incorporated...
Communique

RECOVERY Trial publishes tocilizumab results

12 February, 2021
The Taskforce notes the publication of results of the tocilizumab arm of the RECOVERY trial in medRxiv Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results...
News

Communique # 38

11 February, 2021
Message from the Taskforce Chair Dear colleagues As we enter the second year of the COVID-19 pandemic it is timely to acknowledge the important role of the Taskforce’s...
Communique

Taskforce recommendation for tocilizumab unchanged

29 January, 2021
The Taskforce Disease Modifying Treatments and Chemoprophylaxis Panel and the Guidelines Leadership Group have incorporated the results of the tocilizumab arm of the REMAP-CAP trial (published as a pre-print on January 7,...
News